Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.6B 16.43B 15.07B 28.22B 1,918B 28.91B 195B 76.17B 949B 75.19B 73.56B 3,281B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.98B 17.71B 16.26B 30.43B 2,069B 31.18B 210B 82.14B 1,024B 81.08B 79.32B 3,539B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
6 months+2.55%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 38.81
Extreme 38.8118
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
110.05
10 years 13.05
Extreme 13.05
159.54
Date Insider Type Main position Quantity % Market Cap.
3/23/26 Issuer sale

Chief Administrative Officer

90,092 0.0472%
3/23/26 Issuer sale

Director

16,381 0.0086%
3/23/26 Free

Executive/Senior Manager

254,111 0.1331%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+120.68%+5.93% 20.03B
+0.11%-3.96%+127.67%+98.26% 4.45B
+0.18%+2.78%+117.13%+179.55% 3.61B
-2.98%-11.80%+56.16%-36.67% 2.04B
+0.89%-0.43%-30.47%-37.50% 2.12B
-0.95%-6.27%+178.38%+217.29% 1.83B
-3.94%-7.18%+165.73%-42.45% 972M
-2.86%-5.39%-15.73%+18.65% 799M
+1.04%+1.62%-39.58%-14.85% 502M
-10.56%-1.86%-5.51% - 407M
Average -1.81%-3.98%+67.45%+43.13% 3.67B
Weighted average by Cap. +0.12%-1.53%+106.41%+38.90%

Financials

2024 2025
Net sales 2.76B 2.42B 2.26B 2.08B 3.89B 264B 3.98B 26.83B 10.49B 131B 10.36B 10.13B 452B 3.25B 2.85B 2.66B 2.44B 4.58B 311B 4.69B 31.58B 12.35B 154B 12.19B 11.93B 532B
Net income -1.03B -904M -844M -774M -1.45B -98.55B -1.49B -10.01B -3.91B -48.77B -3.86B -3.78B -169B -208M -183M -171M -157M -293M -19.92B -300M -2.02B -791M -9.86B -781M -764M -34.07B
Net Debt 1.74B 1.53B 1.43B 1.31B 2.45B 166B 2.51B 16.9B 6.61B 82.36B 6.52B 6.38B 285B 1.57B 1.38B 1.29B 1.18B 2.21B 150B 2.27B 15.27B 5.97B 74.42B 5.9B 5.77B 257B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock